GLP-1 microdosing, explained
Standard GLP-1 dosing is designed for meaningful weight loss in patients who meet clinical criteria. But a growing group of patients is asking a different question: can smaller doses support metabolic health without the stronger appetite suppression? That's the idea behind microdosing.
Smaller doses, different goal
Microdosing uses a fraction of standard GLP-1 doses. The aim isn't dramatic weight change — it's supporting insulin sensitivity, steadier blood sugar, and gentler appetite regulation. The approach is intentionally calibrated to avoid significant weight loss.
Who tends to choose it
Patients managing early signs of insulin resistance such as prediabetes, people who are overweight but don't meet BMI criteria for higher-dose therapy, those who felt over-suppressed on standard dosing, and longevity-focused patients thinking in decades rather than pounds.
What to expect
Microdosing is gradual by design. Some patients notice softer food noise within a few weeks; broader metabolic effects build over months and show up in lab work rather than the mirror. A lab panel 60–90 days after starting — and annually after that — lets your clinician see how your body is responding. Results vary and are not guaranteed.
Important context
Microdose GLP-1 therapy is prescribed off-label at lower doses for metabolic support, and compounded formulations are prepared by state-licensed pharmacies based on a clinician's prescription — they are not FDA-approved as finished drug products. A licensed clinician determines whether this approach is appropriate for you.
Curious if it's right for you?
Start with a short online visit — a licensed clinician reviews your history before anything is prescribed.
This article is for general information only and does not provide medical advice. Prescription products require evaluation by a licensed clinician. Individual results vary and are not guaranteed.
